NCT07929831 The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity
| NCT ID | NCT07929831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Radboud University Medical Center |
| Condition | Obesity & Overweight |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-08-28 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-08-28 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity. The main questions this study aims to answer are: * What is the composition of weight loss during incretin treatment? * What is the composition of recurrent weight gain after stopping incretin treatment? An additional question this study aims to answer is: \- How do muscle strength and physical function change during and after incretin treatment? Two groups of patients will be included: patients who start with incretin therapy for overweight/obesity and patients who stop incretin therapy for overweight/obesity. Participants who start incretin treatment will have measurements before starting treatment, after six months, and after twelve months or when treatment is stopped. Participants who stop incretin treatment will have measurements before stopping treatment, after six months, and after twelve months or before restarting treatment. Measurements include: * Height, length, waist circumference * Body composition measured with InBody, with a Dual-Energy X-ray Absorptiometry in a subgroup of the participants * Muscle strength tests * Physical function tests * Blood samples to asses metabolic health * Physical activity measured with an activity monitor (ActivPAL) * Questionnaires about health, incretin treatment, physical activity, and diet No treatment or medication will be given as part of the study. Participants will receive incretin treatment as part of their usual care.
Eligibility Criteria
Inclusion Criteria: * Screened and planned to start with incretin treatment or currently using incretin and planned to discontinue treatment. * Aged 18 years or older Exclusion Criteria: * Inability to comprehend scheduled procedures (e.g., language barriers) * Unable to perform the physical tests due to physical disabilities * Patients who underwent MBS or including endoscopic interventions and gastric balloon placement. * Prior use of incretins, or other obesity medication.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07929831 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07929831 currently recruiting?
Yes, NCT07929831 is actively recruiting participants. Contact the research team at puck.vandenhooff@radboudumc.nl for enrollment information.
Where is the NCT07929831 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands, Nieuwegein, Netherlands.
Who is sponsoring the NCT07929831 clinical trial?
NCT07929831 is sponsored by Radboud University Medical Center. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.